CG ONCOLOGY INC (CGON)
Health Care · Clinical-stage immuno-oncology · NASDAQ
An early-stage immuno-oncology company developing cretostimogene, a novel therapeutic candidate for high-risk and intermediate-risk non-muscle-invasive bladder cancer (NMIBC).
What CG ONCOLOGY INC does
CG Oncology is a clinical-stage biopharmaceutical company focused on developing cretostimogene, an investigational immunotherapy for non-muscle-invasive bladder cancer (NMIBC). The company is advancing its lead candidate through clinical development with the goal of commercialization. CG Oncology has recently achieved early commercial revenue from development and licensing activities while continuing to conduct research and development for its oncology pipeline.
Themes: ["Immunotherapy / bladder cancer"]
Fundamentals
- Price$73.32 as of 2026-07-09 close
- Market cap$6.2B as of 2026-07-10
- 1-year return+168.9% as of 2026-07-09 close
- Net margin-2865.7% as of 2026-07-10
- Gross margin-15.0% as of 2026-07-10
- ROE-23.3% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+666.0% as of 2026-07-10
- Beta0.20 as of 2026-07-10
Key risks (from latest filing)
["Clinical development risk: Success of cretostimogene depends on achieving positive clinical trial results and obtaining regulatory approvals; failure in clinical trials could render the program unviable."]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.